Importantly, the implications of statin-mediated PAR-2 modulation may extend beyond the cancer cell itself to include alterations in the surrounding stromal and adipose compartments, particularly peritumoral adipose tissue (PTAT), which is increasingly recognized as a metabolically active and immunologically dynamic contributor to tumour progression. Here, F2RL1 is linked to cancer.